First Light Asset Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), First Light Asset Management, LLC reported 31 stock positions worth $1.6 billion. Its top holding was Neogenomics (NEO) at 10.9% of the portfolio, followed by Si-Bone (SIBN, 8.1%) and Axogen (AXGN, 7.7%). Compared with Q1 2026, it opened 2 new positions, sold out of 6, added to 17 and reduced 12. The biggest buy was Neogenomics (NEO, shares +26%) and the biggest sale an exit from Centessa Pharmaceuticals (CNTA).
- Most Recent 13F
- Q2 2026
- Location
- Edina, MN
- CIK
- 0001600004
- Portfolio Value
- $1.6B (Q2 2026)
- SEC Filing
- 0001999371-26-018014 ↗ filed Aug 14, 2026
Holdings Value
Holdings 31 stocks · $1.6B
| NEO Neogenomics Inc. | 10.89% | 12,279,523 | $179.2M | Add +26.2% |
| SIBN Si-Bone Inc. | 8.06% | 8,127,985 | $132.6M | Add +51.8% |
| AXGN Axogen Inc. | 7.72% | 2,748,361 | $126.9M | Reduce -31.3% |
| APGE Apogee Therapeutics Inc. | 7.50% | 930,289 | $123.5M | Add +61.3% |
| PVLA Palvella Therapeutics Inc. | 7.17% | 771,901 | $118.0M | Reduce -21.3% |
| TWST Twist Bioscience Corp. | 4.55% | 727,933 | $74.9M | Reduce -17.2% |
| ELVN Enliven Therapeutics Inc. | 4.20% | 1,360,750 | $69.1M | Add +574.1% |
| GH Guardant Health Inc. | 4.03% | 441,586 | $66.3M | Add +57.5% |
| MASS 908 Devices Inc. | 3.32% | 6,282,804 | $54.7M | Add +3.5% |
| AMLX Amylyx Pharmaceuticals Inc. | 3.30% | 3,023,256 | $54.3M | Reduce -5.3% |
| WGS Genedx Holdings Corp. | 3.27% | 783,923 | $53.8M | Add +222.7% |
| SLP Simulations Plus Inc. | 3.11% | 2,792,677 | $51.1M | Add +6.1% |
| TNDM Tandem Diabetes Care Inc. | 3.10% | 3,383,553 | $51.1M | Add +157.4% |
| CRNX Crinetics Pharmaceuticals Inc. | 3.10% | 1,360,866 | $50.9M | Add +24.9% |
| NPCE Neuropace Inc. | 2.76% | 2,861,167 | $45.5M | Add +16.3% |
| EWTX Edgewise Therapeutics Inc. | 2.70% | 1,095,171 | $44.5M | Add +9.3% |
| ANAB Anaptysbio Inc. | 2.39% | 582,004 | $39.3M | Add +2.9% |
| TRVI Trevi Therapeutics Inc. | 2.38% | 2,097,215 | $39.1M | New |
| SEPN Septerna Inc. | 1.96% | 963,260 | $32.3M | Add +31.4% |
| TLSI Trisalus Life Sciences Inc. | 1.81% | 6,552,491 | $29.8M | Add +29.3% |
| TECX Tectonic Therapeutic Inc. | 1.67% | 800,726 | $27.5M | Add +23.6% |
| HCAT Health Catalyst Inc. | 1.55% | 12,810,861 | $25.5M | Reduce -0.5% |
| BFLY Butterfly Network Inc. | 1.35% | 2,642,404 | $22.2M | Reduce -0.7% |
| ESTA Establishment Labs Holdings | 1.29% | 246,577 | $21.2M | Reduce -19.9% |
| PCVX Vaxcyte Inc. | 1.22% | 345,157 | $20.1M | Add +143.4% |
| IRTC Irhythm Holdings Inc. | 1.21% | 167,092 | $19.9M | Reduce -0.6% |
| OMCL Omnicell Inc. | 1.14% | 452,324 | $18.8M | Reduce -7.7% |
| ATRC Atricure Inc. | 0.97% | 567,838 | $15.9M | Reduce -22.2% |
| KRMD Koru Medical Systems Inc. | 0.86% | 3,387,902 | $14.2M | Reduce -10.1% |
| TCMD Tactile Systems Technology I | 0.84% | 462,562 | $13.8M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 0.58% | 85,765 | $9.5M | Reduce -1.6% |
Portfolio Sells Q1 2026 → Q2 2026
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −5.56 |
| AXGN Axogen Inc. | Reduce -31.3% | 7.72% | −4.17 |
| PVLA Palvella Therapeutics Inc. | Reduce -21.3% | 7.17% | −3.79 |
| WVE Wave Life Sciences Ltd. | Sold out | 0.00% | −1.20 |
| VERA Vera Therapeutics Inc. | Sold out | 0.00% | −1.13 |
| MDXG Mimedx Group Inc. | Sold out | 0.00% | −1.01 |
| ATRC Atricure Inc. | Reduce -22.2% | 0.97% | −0.90 |
| SGP Spyglass Pharma Inc. | Sold out | 0.00% | −0.87 |
| ORGO Organogenesis Holdings Inc. | Sold out | 0.00% | −0.74 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -5.3% | 3.30% | −0.67 |
| KRMD Koru Medical Systems Inc. | Reduce -10.1% | 0.86% | −0.59 |
| IRTC Irhythm Holdings Inc. | Reduce -0.6% | 1.21% | −0.57 |
| OMCL Omnicell Inc. | Reduce -7.7% | 1.14% | −0.32 |
| ESTA Establishment Labs Holdings | Reduce -19.9% | 1.29% | −0.28 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -1.6% | 0.58% | −0.10 |
| HCAT Health Catalyst Inc. | Reduce -0.5% | 1.55% | +0.08 |
| BFLY Butterfly Network Inc. | Reduce -0.7% | 1.35% | +0.39 |
| TWST Twist Bioscience Corp. | Reduce -17.2% | 4.55% | +0.81 |
Portfolio Buys Q1 2026 → Q2 2026
| NEO Neogenomics Inc. | Add +26.2% | 10.89% | +4.42 |
| ELVN Enliven Therapeutics Inc. | Add +574.1% | 4.20% | +3.49 |
| APGE Apogee Therapeutics Inc. | Add +61.3% | 7.50% | +3.16 |
| TRVI Trevi Therapeutics Inc. | New | 2.38% | +2.38 |
| SIBN Si-Bone Inc. | Add +51.8% | 8.06% | +2.00 |
| WGS Genedx Holdings Corp. | Add +222.7% | 3.27% | +1.87 |
| GH Guardant Health Inc. | Add +57.5% | 4.03% | +1.71 |
| TNDM Tandem Diabetes Care Inc. | Add +157.4% | 3.10% | +0.84 |
| TCMD Tactile Systems Technology I | New | 0.84% | +0.84 |
| PCVX Vaxcyte Inc. | Add +143.4% | 1.22% | +0.48 |
| SEPN Septerna Inc. | Add +31.4% | 1.96% | +0.38 |
| SLP Simulations Plus Inc. | Add +6.1% | 3.11% | +0.32 |
| TLSI Trisalus Life Sciences Inc. | Add +29.3% | 1.81% | −0.00 |
| MASS 908 Devices Inc. | Add +3.5% | 3.32% | −0.01 |
| TECX Tectonic Therapeutic Inc. | Add +23.6% | 1.67% | −0.12 |
| EWTX Edgewise Therapeutics Inc. | Add +9.3% | 2.70% | −0.12 |
| NPCE Neuropace Inc. | Add +16.3% | 2.76% | −0.14 |
| ANAB Anaptysbio Inc. | Add +2.9% | 2.39% | −0.42 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +24.9% | 3.10% | −0.45 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 31 | $1.6B | NEO, SIBN, AXGN, APGE, PVLA |
| Q1 2026 | 35 | $1.1B | AXGN, PVLA, NEO, SIBN, CNTA |
| Q4 2025 | 33 | $1.3B | AXGN, NEO, SIBN, PVLA, CNTA |
| Q3 2025 | 41 | $1.1B | AXGN, PHLT, CNTA, NEO, AMLX |
| Q2 2025 | 38 | $771.3M | ANAB, CNTA, PHLT, NEO, AXGN |
| Q1 2025 | 37 | $875.7M | ANAB, AXGN, CNTA, NEO, TWST |
| Q4 2024 | 36 | $1.0B | FNA, CNTA, AXGN, ATRC, TWST |
| Q3 2024 | 38 | $1.2B | CNTA, FNA, EVH, AXGN, ATRC |
| Q2 2024 | 44 | $1.1B | FNA, ATEC, CRNX, NEO, XENE |
| Q1 2024 | 50 | $1.3B | CRNX, ATEC, NTRA, XENE, PLRX |